Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

Daix , Long Island City , August 31, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with...

Related Keywords

Qatar ,France ,Paris ,France General ,United Kingdom ,New York ,United States ,Daix ,Bourgogne ,America ,French ,Aude Lepreux ,Pascaline Clerc ,Pierre Broqua ,David Nikodem ,Euronext ,European Investment Bank ,Nasdaq ,European Parliament ,Enterprise Associates ,Patricial Bank ,European Union ,Financial Services ,Global External Affairs ,Qatar Holding ,Company Board Of Directors ,Brunswick Group ,Long Island City ,Euronext Paris ,Capital Increase ,Chief Executive Officer ,Royalty Certificates ,New Shares ,French Commercial Code ,Yiheng Capital ,Sofinnova Partner ,Sole Agent ,French Autorit ,Registration Document ,Securities Note ,Nasdaq Global Market ,Global External ,Roquet Montegon ,Des March ,Universal Registration Document ,French Code ,Prospectus Regulation ,Member State ,European Economic Area ,Markets Act ,Financial Promotion ,Relevant Persons ,Securities Act ,Markets ,